Latham & Watkins Advises Norgine on Sale to Goldman Sachs Asset Management
Latham & Watkins has advised Norgine Europe B.V., a leading European specialty pharmaceutical company, on its agreement to sell a controlling stake in the company to Goldman Sachs Asset Management.
Norgine has brought transformative medicines to patients for over a century. With direct presence in 16 European countries, as well as Australia and New Zealand, Norgine helped 24 million patients around the world access life-changing medicines in 2021.
The Latham team was led by London corporate partner Robbie McLaren, with partner Linzi Thomas and associates Samantha Peacock, Lachlan Ferguson, Syavie Ghamry, Jacopo Eftekhar Zonouzi, Edward Coates, and Michael Houlder. Advice was also provided on life sciences regulatory matters by Paris partner Eveline Van Keymeulen, with London associate Sara Patel; on data and technology matters by London partner Gail Crawford, with associates Oliver Mobasser, Randi Barman, and Nara Yoo; on tax matters by Chicago partner Diana Doyle and London partner Karl Mah, with London counsel James Leslie, London associate Mimi Kyprianou, and Chicago associate Michael Zucker; on employment matters by London associates Paul Lawrence and Erin McKirdy; on environmental matters by London partner Paul Davies, with counsel Michael Green and associate James Bee; on real estate matters by London partner Quentin Gwyer, with associate Danni Davies; on antitrust matters by Brussels partner Hector Armengod, with counsel Philipp Studt; on disputes matters by London counsel Daniel Smith, with associates Harriet Slater and Thomas Lane; and on finance matters by London partner Fergus O’Domhnaill, with associates Julie Van der Meersche and Alice Au.